.png)
News | January 28, 2025
Devyser wins tender in Italy for its cystic fibrosis NGS test worth up to 5.4 million SEK
Find out more
News (2)
Devyser Capital Markets Day 2024
Devyser at 20: Celebrating two decades of innovation in genetic diagnostics
.png)
Devyser seeks to secure FDA approval for NGS test for kidney transplant monitoring
Devyser Compact achieves Class III approval in China
Devyser to share data at ASHI 2024 demonstrating its innovations and studies within transplantation
.png)
Devyser Diagnostics AB publishes quarterly report for the period April to June 2024
“Devyser continued to report high sales growth in the second quarter. Organic growth compared with...
.png)
Devyser wins tender in Italy for its cystic fibrosis NGS test worth up to 5.9 million SEK
.png)
Devyser wins tender in Sweden for Thalassemia NGS testing worth up to 8.4 million SEK
Devyser announces expanded commercial agreement with Thermo Fisher Scientific for post-transplant monitoring NGS products
Devyser launches updated Y-Chromosomal microdeletion test
